 |
|
Reversible Cystoid Macular Edema Secondary to Fingolimod in a Renal Transplant Recipient
Georges Saab, MD;
Arghavan Almony, MD;
Kevin J. Blinder, MD;
Rebecca Schuessler, RN;
Daniel C. Brennan, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Renal transplant remains the treatment of choice for end-stage renal disease.1 Unfortunately, long-term graft failure rates are unsatisfactory. One potential therapy is fingolimod (FTY720), a new immunomodulator that reduces lymphocyte recirculation from lymphoid tissue to blood and peripheral tissues.2 We describe a renal transplant recipient in a phase IIIb clinical trial of fingolimod who developed cystoid macular edema (CME).
Report of a Case
A 58-year-old woman with end-stage renal disease from autosomal dominant polycystic kidney disease received a living unrelated renal allograft. Her medical history included anemia of chronic kidney disease, hypertension, and secondary hyperparathyroidism. Initial immunomodulation consisted of fingolimod (5 mg daily), low-dose cyclosporine (6-8 mg/kg daily), and oral prednisone (tapered to 5 mg daily within 1 month of the transplant). Additional medications included trimethoprim-sulfamethoxazole, valganciclovir hydrochloride, nystatin, and famotidine.
The patient was first seen by . . . [Full Text of this Article]
Comment
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
HEMORRHAGING FOCAL ENCEPHALITIS UNDER FINGOLIMOD (FTY720) TREATMENT: A CASE REPORT
Leypoldt et al.
Neurology 2009;72:1022-1024.
FULL TEXT
|
